Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Crescita Therapeutics Inc T.CTX

Alternate Symbol(s):  CRRTF

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial... see more

TSX:CTX - Post Discussion

View:
Post by lscfa on Mar 15, 2024 12:37am

Q4 on sedar

Skincare biz growing. Looking for new customers for their contract manufacturing biz where the plant has a capacity of $25 mil/yr. 

 

 

Skincare

Licensing

Manufacturing

Total rev

ebitda

Dec 23

2,851

1,547

327

4,725

245

Sep 23

2,412

163

458

3,033

(988)

Jun 23

2,685

299

2,178

5,162

214

Mar 23

2,492

21

2,089

4,602

161

Dec 22

2,422

1,481

2,127

6,030

997

Sep 22

1,672

92

4,268

6,032

512

Jun 22

2,392

227

3,893

6,512

646

Mar 22

1,536

0

3,415

4,951

66

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities